The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press32010.17650/1818-8338-2017-11-3-4-10-16EDITORIALРЕДАКЦИОННАЯ СТАТЬЯINTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPYИНТЕРСТИЦИАЛЬНЫЕ ЗАБОЛЕВАНИЯ ЛЕГКИХ: КЛЮЧЕВЫЕ МИШЕНИ ДЛЯ ТЕРАПИИhttps://orcid.org/0000-0003-4669-1006ShostakN. A.ШостакН. А.
Russian Federation

1 Ostrovityanova St., Moscow 117997

Кафедра факультетской терапии им. академика А.И. Нестерова.

117997 Москва, ул. Островитянова, 1

https://orcid.org/0000-0002-7410-9784KlimenkoA. A.КлименкоА. А.
Russian Federation

1 Ostrovityanova St., Moscow 117997

Алеся Александровна Клименко - кафедра факультетской терапии им. академика А.И. Нестерова.

117997 Москва, ул. Островитянова, 1

aaklimenko@yandex.ruhttps://orcid.org/0000-0001-9152-3234KondrashovA. A.КондрашовА. А.
Russian Federation

1 Ostrovityanova St., Moscow 117997

Кафедра факультетской терапии им. академика А.И. Нестерова.

117997 Москва, ул. Островитянова, 1

Russian National Research Medical University named after N.I. Pirogov, Ministry of Health of RussiaФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России15102017113-410160706201807062018Copyright ©; 2017, Shostak N.A., Klimenko A.A., Kondrashov A.A.Copyright ©; 2017, Шостак Н.А., Клименко А.А., Кондрашов А.А.2017Shostak N.A., Klimenko A.A., Kondrashov A.A.Шостак Н.А., Клименко А.А., Кондрашов А.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/320

Interstitial lung diseases (ILDs) are a heterogenous group of disorders and pathological conditions of known and unknown nature characterized by extensive and, generally, bilateral damage of the respiratory part of the lungs (alveoli, respiratory bronchioles). Until recently, there weren’t any effective therapies for patients with progressive pulmonary fibrosis, partly because of limited knowledge of the disease pathogenesis. However, in the last decade, new data of etiological, genetic factors and pathogenetic mechanisms of ILD were obtained. Currently, only two drugs were proven effective for treatment of patients with interstitial pulmonary fibrosis: pirfenidone and nintedanib which affect the rate of progression of restrictive changes in the lungs. The search for drugs is continuing in accordance with the growing understanding of pathogenetic mechanisms of ILDs. Notably, recent years saw an “explosion” of pre-clinical studies.

Интерстициальные заболевания легких (ИЗЛ) – гетерогенная группа заболеваний и патологических состояний известной и неизвестной природы, характеризующиеся распространенным, как правило, двусторонним поражением респираторных отделов легких (альвеол, респираторных бронхиол). До недавнего времени у пациентов с прогрессирующим фиброзом легких эффективной терапии не существовало отчасти из-за ограниченных знаний о патогенезе этого состояния. Однако в последнее десятилетие появились новые данные об этиологических, генетических факторах и патогенетических механизмах ИЗЛ. Препаратами с доказанной эффективностью при лечении больных интерстициальным легочным фиброзом в настоящее время признаны только 2 препарата – пирфенидон и нинтеданиб, влияющие на скорость прогрессирования рестриктивных изменений в легких. Поиск лекарственных препаратов продолжается в соответствии с растущим пониманием патогенетических механизмов ИЗЛ, причем в последнее время наблюдается «взрыв» на уровне доклинических исследований.

interstitial lung diseasesidiopathic pulmonary fibrosisidiopathic interstitial pneumoniasfibrogenesispulmonary hypertensionnintedanibpirfenidonetyrosine-kinase inhibitorselective NOX4 inhibitorglucocorticoidsинтерстициальные заболевания легкихидиопатический легочный фиброзидиопатические интерстициальные пневмониифиброгенезлегочная гипертензиянинтеданибпирфенидонингибитор тирозинкиназселективный ингибитор NOX4глюкокортикоидыClinical guidelines. Interstitial pulmonary fibrosis. Health Ministry of Russia, Russian respiratory society. Revision 2016. Available at: http://spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/. (In Russ.).Клинические рекомендации. Интерстициальный легочный фиброз. Минздрав России, Российское респираторное общество. Пересмотр 2016 г. URL: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165(2):277–304. DOI: 10.1164/ajrccm.165.2.ats01.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165(2):277–304. DOI: 10.1164/ajrccm.165.2.ats01.Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733–48. DOI: 10.1164/rccm.201308-1483ST.Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733–48. DOI: 10.1164/rccm.201308-1483ST.Petrov D.V., Ovsyannikov N.V., Kapralov E.A., Kapustian O.V. Interstitial lung diseases: point of view of the practitioner. Prakticheskaya pul'monologiya = Practical Pulmonology 2014;(1):34–8. (In Russ.).Петров Д.В., Овсянников Н.В., Капралов Э.А., Капустьян О.В. Интерстициальные заболевания легких: точка зрения практического врача. Практическая пульмонология 2014;(1):34–8.Rockey D.C., Bell P.D., Hill J.A. Fibrosis – a common pathway to organ injury and failure. New Engl J Med 2015;372(12):1138–49. DOI: 10.1056/NEJMra1300575.Maher T.M. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012;33(1):69–83. DOI: 10.1016/j.ccm.2011.11.002.Maher T.M. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012;33(1):69–83. DOI: 10.1016/j.ccm.2011.11.002.Woodcock H.V., Maher T.M. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep 2014;6:16. DOI: 10.12703/P6-16.Woodcock H.V., Maher T.M. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep 2014;6:16. DOI: 10.12703/P6-16.Hecker L., Vittal R., Jones T. et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15(9): 1077–81. DOI: 10.1038/nm.2005.Hecker L., Vittal R., Jones T. et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15(9): 1077–81. DOI: 10.1038/nm.2005.Amara N., Goven D., Prost F. et al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65(8):733–8. DOI: 10.1136/thx.2009.113456.Amara N., Goven D., Prost F. et al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65(8):733–8. DOI: 10.1136/thx.2009.113456.Laleu B., Gaggini F., Orchard M. et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010; 53(21):7715–30. DOI: 10.1021/jm100773e.Kinder B.W., Brown K.K., McCormack F.X. et al. Serum surfactant protein A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009;135(6):1557–63. DOI: 10.1378/chest.08-2209.Kinder B.W., Brown K.K., McCormack F.X. et al. Serum surfactant protein A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009;135(6):1557–63. DOI: 10.1378/ chest.08-2209.Ohnishi H., Yokoyama A., Kondo K. et al. Comparative study of KL6, surfactant protein A, surfactant protein D, and monocyte chemoattractant protein1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165(3):378– 81. DOI: 10.1164/ajrccm.165.3.2107134.Oldham J.M., Ma S.F., Martinez F.J. et al. IPFnet Investigators. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015;192(12):1475–82. DOI: 10.1164/rccm.201505-1010OC.Oldham J.M., Ma S.F., Martinez F.J. et al. IPFnet Investigators. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015;192(12):1475–82. DOI: 10.1164/rccm.201505-1010OC.Raghu G., Anstrom K.J., King T.E. et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366(21):1968–77. DOI: 10.1056/NEJMoa1113354.Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760–9. DOI: 10.1016/S0140-6736(11)60405-4.Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760–9. DOI: 10.1016/S0140-6736(11)60405-4.Oku H., Shimizu T., Kawabata T. et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590(1–3): 400–8. DOI: 10.1016/j.ejphar.2008.06.046.King T.E. Jr., Bradford W.Z., Castro-Bernardini S. et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083–92. DOI: 10.1056/NEJMoa1402582.King T.E. Jr., Bradford W.Z., Castro-Bernardini S. et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083–92. DOI: 10.1056/NEJMoa1402582.Richeldi L., Collard H.R., Jones M.G. Idiopathic pulmonary fibrosis. Lancet 2017;389(10082):1941–52. DOI: 10.1016/S0140-6736(17)30866-8.Richeldi L., Collard H.R., Jones M.G. Idiopathic pulmonary fibrosis. Lancet 2017;389(10082):1941–52. DOI: 10.1016/S0140-6736(17)30866-8.Richeldi L., du Bois R.M., Raghu G. et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071–82. DOI: 10.1056/NEJMoa1402584.Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157–79. DOI: 10.1146/annurev-pathol-012513-104706.Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157–79. DOI: 10.1146/annurev-pathol-012513-104706.Wolters P.J., Blackwell T.S., Eickelberg O. et al. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med 2018;6(2):154–60. DOI: 10.1016/S22132600(18)30007-9.Svegliati S., Spadoni T., Moroncini G., Gabrielli A. NADPH oxidase, oxidative stress and fibrosis in Systemic Sclerosis. Free Radic Biol Med 2018. PII: S08915849(18)30731-7. DOI: 10.1016/j.freeradbiomed.2018.04.554.Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006;44(5):372–6. DOI: 10.1016/j.vph.2006.01.013.Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006;44(5):372–6. DOI: 10.1016/j.vph.2006.01.013.